AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.
Overview
Choosing between AbbVie (NYSE:ABBV) and Bristol-Myers Squibb (NYSE:BMY) requires weighing high-growth immunology assets against deep value as both drugmakers navigate a shifting landscape of patent expirations and drug pricing reforms.
AbbVie focuses on specialty immunology and aesthetics, pivoting past its Humira legacy. Bristol-Myers Squibb emphasizes oncology and cardiovascular health while transitioning to its next-generation pipeline. Both companies are major players in the pharmaceutical industry, appealing to income-seeking investors through consistent dividends and stable cash flows.
Details
AbbVie is a global biopharmaceutical company that delivers innovative medicines across roughly 180 countries. The company is a major player among pharmaceutical stocks, maintaining manufacturing facilities in roughly 20 countries. Its primary U.S. sales are concentrated among three major wholesale distributors, including McKesson Corporation, Cardinal Health, and Cencora, though no single wholesaler accounted for more than 43% of total U.S. gross revenues in 2025.
Source
Originally published at www.fool.com.